| Name | Title | Contact Details |
|---|
Avigen, Inc. is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kellogg Community Federal Credit Union is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lancaster, PA. To find more information about Kellogg Community Federal Credit Union, please visit www.kelloggcfcu.org
St. Cloud Regional Medical Center is situated in the heart of St. Cloud, Florida. The modern 84-bed, acute care facility offers a comprehensive medical support system for both inpatient and outpatient needs. St. Cloud Regional Medical Center has always been committed to offering the highest level of compassionate care. Our physicians and staff are dedicated to delivering this care in an environment that is efficient and comfortable. St. Cloud Regional Medical Center staff is comprised of physicians ranging from family practice, internal medicine and general surgery. These professionals are highly skilled in their fields and are at the core of the great healthcare that we deliver to the residents of Osceola County.
Cavapharma is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.